IL1B and myocardial infarction: HF patients have elevated levels of circulating pro-inflammatory cytokines including IL-6, IL-1β, and TNFα, and recent analysis of the results of the CANTOS phase III clinical trial revealed that use of the anti-IL-1β monoclonal antibody canakinumab (Ilaris), reduced hospitalizations and mortality related to HF in MI-patients.96